<DOC>
	<DOCNO>NCT01966393</DOCNO>
	<brief_summary>Closed-loop strategy compose three component : glucose sensor read glucose level , insulin pump infuse insulin dose mathematical algorithm decide required insulin dosage base sensor 's reading . A dual-hormone closed-loop strategy would regulate glucose level infusion two hormone : insulin glucagon . The main objective project compare efficacy single-hormone closed-loop strategy , dual-hormone closed-loop strategy conventional insulin pump therapy regulate glucose level 60-hours non-standardized condition adult type 1 diabetes . The investigator hypothesize 1 ) Controlling glucose level use single- dual-hormone CLS feasible free-living condition long period time ( 60 hour ) ; 2 ) Dual-hormone CLS superior single-hormone CLS assess reduce time spend hypoglycemic range ; 3 ) Both single-hormone dual-hormone CLS superior conventional pump therapy .</brief_summary>
	<brief_title>Closed-loop Control Glucose Levels ( Artificial Pancreas ) 60 Hours Adults With Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Males female ≥ 18 year old . Clinical diagnosis type 1 diabetes least one year . The subject insulin pump therapy least 3 month . HbA1c ≤ 12 % . Clinically significant nephropathy , neuropathy retinopathy judge investigator . Recent ( &lt; 6 month ) acute macrovascular event e.g . acute coronary syndrome cardiac surgery . History pheochromocytoma insulinoma ( glucagon could induce hormonal response tumor ) Beta‐blockers high dose base investigator 's evaluation dosage interference glucagon ( glucagon modify effect betablockers , mostly evident high dos ) Chronic indometacin treatment ( prevent glucagon effect liver thus ability raise glucose ) Warfarin chronic treatment INR monitoring evaluate ( increase risk bleed ) Anticholinergic drug ( risk interaction ) Pregnancy . Severe hypoglycemic episode within two week screen . Current use glucocorticoid medication ( except low stable dose inhaled steroid ) . Known suspect allergy trial product meal content ( gluten free menu available ) . Other serious medical illness likely interfere study participation ability complete trial judgment investigator ( e.g . need major revision carbohydrate counting ) . Anticipating significant change exercise regimen admission ( i.e . start stop organize sport ) . Failure comply team 's recommendation ( e.g . willing eat meals/snacks , willing change pump parameter , etc ) . Treatments could interfere glucagon</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Type 1 diabetes</keyword>
	<keyword>Hypoglycemia</keyword>
	<keyword>Insulin</keyword>
	<keyword>Glucagon</keyword>
	<keyword>Closed-loop strategy</keyword>
	<keyword>Artificial pancreas</keyword>
</DOC>